LY2880070 is an orally active CHK1 inhibitor. LY2880070 can be used as an anticancer agent and shows promising results in preclinical models of pancreatic ductal adenocarcinoma (PDAC) when combined with DNA damaging agents.

 

Brand: BCM

 

Target: Chk

 

Signaling Pathways: Cell Cycle/Checkpoint

 

Boiling Point: 575.3±50.0 °C(Predicted)

 

pKa: 10.34±0.10(Predicted)

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

Isomeric SMILES: CC1=NC(=C(C=C1)C2=CC(=NN2)NC3=CN=CC(=N3)O[C@@H]4CCCNC4)OC  

 

InChIKey: LAEFIEWPUJMANC-CYBMUJFWSA-N  

 

InChI: InChI=1S/C19H23N7O2/c1-12-5-6-14(19(22-12)27-2)15-8-16(26-25-15)23-17-10-21-11-18(24-17)28-13-4-3-7-20-9-13/h5-6,8,10-11,13,20H,3-4,7,9H2,1-2H3,(H2,23,24,25,26)/t13-/m1/s1

 

Attribute
[Chem Name]	N-[5-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-3-yl]-6-[(3R)-piperidin-3-yl]oxypyrazin-2-amine
[Synonym]	LY2880070
[CAS No.]	1375637-35-6
[MDL No.]	MFCD32669804
[Formula]	C19H23N7O2
[Molecular]	381.43
[Form]	Solid Powder
[Storage]	Keep in dark place. Inert atmosphere, 2-8°C

Goods Tag